Ruxolitinib, a kinase inhibitor, inhibits Janus Associated Kinases (JAKs), JAK1 and JAK2, which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis… Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA FAERS, and CMS NADAC pricing.
Loading full data from Know Your Drugs Institute…